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Liver functional abnormalities were seen in 13 (19.7%) 
of 66 recipients of cadaveric renal homo grafts treated 
with cyclosporin A and prednisone. However, such pre-
sumed hepatotoxicity was a minor problem in the use of 
cyclosporin A. The complication was less frequent th.an 
that of nephrotoxicity, was as easily manageable With 
reductions in the cyclosporin A dosage, and generally 
did not cause clinical illness. In an occasional case, late 
hepatotoxicity can force a therapeutic change from cy-
closporin A to azathioprine, but careful consideration 
should be given to the dangers of subsequent rejection. 
When cyclosporin A (Cy A), an immunosuppressive agent 
discovered (1,2) and produced by the Sandoz Corporation, was 
fIrst being used in humans by Calne et al. in 1978 (3), hepatic 
dysfunction was noted in some of the patients, which has since 
been noted by others (4, 5). The purpose of this paper is to 
clinically analyze the incidence, the manageability, and the 
consequences of this side effect. 
MATERIALS AND METHODS 
Between December 22, 1979 and September 28, 1980, 66 
patients received 67 cadaveric kidneys at the University of 
Colorado Health Sciences Center. Nine of the 66 recipients 
were given their second or third homograft. The renal function 
and the fate of the patients have recently been reported in 
detail elsewhere (6). 
A total of 6 patients of the 66 were hepatitis B surface antigen 
(HBsAg)-positive preoperatively. One patient had cirrhosis of 
the liver prior to the renal transplantation. No liver biopsies 
were obtained in the 66 patients. 
Immunosuppression. A dose (or doses) of 17.5 mg/kg/day of 
Cy A was given orally prior to surgery and usually maintained 
for 8 weeks postoperatively. Usually, the dose was then lowered 
to the 10 mg/kg/day range. This decrease was done earlier in 
the event of serious nephro- or hepatotoxicity. 
Prednisone was given concomitantly with the Cy A in most 
patients. In all adults after the fIrst 20 cases, 200 mg/day was 
given on the day of operation. The dose was tapered by 40 mg 
daily for 4 days. On day 5, the dose was reduced by 20 mg to 
reach the maintenance dose of 20 mg/day. 
If rejection intervened, it was treated by an intravenous bolus 
1 This work was supported by grants from the Veterans Administra-
tion, Grants AM-17260 and AM-07772 from the National Institutes of 
Health, and Grants RR-00051 and RR-00069, from the General Clinical 
Research Centers Program of the Division of Research Resources, 
National Institutes of Health. Presented at the Seventh Annual Sci-
entific Meeting of the American Society of Transplant Surgeons, Chi-
cago, Illinois, June 5 to 7, 1981. 
2 To whom requests for reprints should be addressed, at Department 
of Surgery, University of Pittsburgh School of Medicine, 1084 Scaife 
Hall, Pittsburgh, Pennsylvania 15261. 
of 1 g of methylprednisone or hydrocortisone and the oral 
prednisone was temporarily increased. Cyclosporin was not 
increased. 
RESULTS 
Thirteen patients had at least one episode of hepatotoxicity, 
defIned as a rise in bilirubin over 2.0 mg/IOO ml (34.2 mmol/ 
liter). One of the 13 patients was HBsAg positive before trans-
plantation. 
Early toxicity. Eleven of these 13 patients (16.7% of the 66) 
showed signs of hepatotoxicity 2 weeks to 2 months after the 
transplant (Table 1). It occurred 4.9 ± 1.9 (SE) weeks postop-
eratively. The cyclosporin at the time was 17.7 ± 1.1 (SE) mg/ 
kg/day, range 15.9 to 19.5 mg/kg/day. The peak total bilirubin 
averaged 3.9 ± 1.6 (SE) mg/IOG ml (66.7 ± 27.4 (SE) p,mol/ 
liter). After Cy A was lowered to 10.6 ± 1.9 (SE) mg/kg/day, 
the bilirubin normalized «1.5 mg/l00 mg «25.7 p,mol/liter» 
within a few days. None ofthe patients were ill. 
Late toxicity. Late toxicity manifested itself in patients 1, 12, 
and 13 (Table 2). One of these patients had previously had 
early hepatotoxicity which receded with dose reduction. The 
late toxicity occurred at 13, 8, and 7 months after transplanta-
tion. The bilirubin ranged from 2.5 (42.8 p,mol/liter) to 6.0 mg/ 
100 ml (102.6 p,mol/liter). The three patients were changed 
from Cy A and prednisone to azathioprine and prednisone. 
Patients 12 and 13 also had nephrotoxicity as an indication for 
this therapeutic change. Patient 1 had normal kidney function 
both before and after the change in immunosuppression. All 
patients had their liver functions return to normal within a few 
days after the adjustments in therapy were made. Their sub-
sequent serum bilirubin levels ranged from 0.6 to 0.9 mg/IOO 
ml (10.3 to 15.4 p,mol/liter). 
Other liver function tests. In the 13 patients whose total 
bilirubin increased, nonconjugated bilirubin was responsible for 
50% of the rise. The changes in other liver values were nonspe-
cifIc. SGOT and SGPT stayed within normal limits in one-half 
of the patients and in the other half of the numbers rose to 
three times normal. Alkaline phosphatase stayed normal or just 
over the normal limit. Seven of the 13 patients were on other 
potentially liver-toxic drugs (six on cimetidine and three on 
isoniazid). These drugs were not changed during the toxic 
episodes. 
DISCUSSION 
The two most serious side effects of cyclosporin are nephro-
toxicity and hepatotoxicity. We have previously analyzed the 
nephrotoxicity in liver transplant patients (7). Although the 
incidence of nephrotoxicity at Cy A dose levels of 17 mg/kg/ 
day was 50%, this complication could easily be managed and 
proved to be highly reversible with dose reduction. 
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TABLE 1. Early Cy A hepatotoxicity in cadaveric renal transplants 
Time of Before dose adjustment After dose adjustment 
Patient postoperative hepatotoxicity Total bilirubin (weeks) (mg/loo m1 (lLffiol/liter» 
8 2.1 (35.9) 
2 5 2.5 (42.8) 
3 4 6.6 (112.9) 
4 5 5.5 (94.1) 
5 4 4.5 (77.0) 
6 8 4.0 (68.4) 
7 3 6.3 (107.7) 
8 5 2.9 (49.6) 
9 7 2.3 (39.3) 
10 2 2.2 (37.6) 
11 3 3.8 (65.0) 
Mean ± SE 4.9 ± l.9 3.9 ± l.6 
(66.7 ± 27.4) 
TABLE 2. Late Cy A hepatotoxicity in cadaveric renal transplants 
Patient 
12 
13 
Time of 
postoperative 
hepatotoxicity (months) 
13 
8 
7 
Total 
bilirubin 
(mg/loo ml (,umol!liter) ) 
6.0 (102.6) 
2.9 (49.6) 
2.5 (42.8) 
Cy A dose 
(mg/kg/day) 
5.0 
B.9 
7.0 
Total bilirubin 
after change 
from Cy A to 
azathioprine (mg/loo ml 
("mol/liter)) 
0.6 (10.3) 
0.9 (15.4) 
0.9 (15.4) 
In this study, a 16.7% incidence of hepatotoxicity occurred 
within 2 months after transplantation. As with the nephrotox-
icity, the hepatotoxicity receded rapidly with dose reduction. 
In three patients with late hepatotoxicity, the dose was 
already so low that it was not thought to be safe to reduce it 
further. Subsequent experience has shown this anxiety to be 
unfounded. Doses of 7 to 8.9 mg/kg/day as in patients 12 and 
13 have been shown to be immunosuppressive as well as safe 
(6). The exact lower limits of acceptability are not clear. If late 
serious hepatotoxic side effects occur on daily doses as low as 
5 mg/kg/day, a change from Cy A to azathioprine may be in 
order. 
At the time of this study, serum levels of Cy A could not be 
obtained in the North American continent. Whether the phe-
nomenon of late occurring toxicity in the use of Cy A is 
attributable to changes in the absorption, in metabolism, or in 
tissue accumulation of the drug needs to be resolved in future 
studies which should include plasma levels. 
Cy A dose Total bilirubin Cy A dose (mg/kg/day) (mg/loo m1 (,umol/liter)) (mg/kg/day) 
19.3 1.3 (22.2) 10.0 
17.5 1.2 (20.5) 9.0 
18.5 1.0 (17.1) 14.0 
16.9 1.9 (32.5) 7.9 
17.5 1.1 (18.8) 13.9 
19.5 1.0 (17.1) 8.9 
16.6 1.4 (23.9) 9.2 
17.5 0.6 (10.3) 11.5 
19.0 1.1 (18.8) 10.6 
17.5 1.5 (25.7) 10.0 
15.9 0.7 (12.0) 11.3 
17.7 ± 1.1 1.2 ± 0.3 10.6 ± 1.9 
(20.5 ± 5.1) 
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